Text Size
Trial record 5 of 6 for:    "Albrights hereditary osteodystrophy"
Previous Study | Return to List | Next Study

Study of the Regulation of Parathyroid Hormone Secretion in Pseudohypoparathyroidism

This study has been completed.
Sponsor:
Collaborator:
University of California, Los Angeles
Information provided by:
Office of Rare Diseases (ORD)
ClinicalTrials.gov Identifier:
NCT00004661
First received: February 24, 2000
Last updated: June 23, 2005
Last verified: December 2001
History of Changes
  Purpose

OBJECTIVES:

Determine the relationship between serum calcium concentrations and parathyroid hormone secretion in patients with pseudohypoparathyroidism.


Condition
Pseudohypoparathyroidism

Study Type: Observational
Study Design: Primary Purpose: Screening

Further study details as provided by Office of Rare Diseases (ORD):

Estimated Enrollment: 20
Study Start Date: May 1993
Detailed Description:

PROTOCOL OUTLINE:

Patients are tested for parathyroid hormone response following sequential graded intravenous infusions of sodium citrate and calcium gluconate. Assays include ionized calcium and intact parathyroid hormone.

  Eligibility

Ages Eligible for Study:   12 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

PROTOCOL ENTRY CRITERIA:

--Disease Characteristics-- Pseudohypoparathyroidism, i.e.: Renal resistance to parathyroid hormone OR Albright hereditary osteodystrophy No other illness unless related to pseudohypoparathyroidism No pregnant women

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00004661

Sponsors and Collaborators
National Center for Research Resources (NCRR)
University of California, Los Angeles
Investigators
Study Chair: Mitchell E. Geffner University of California, Los Angeles
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00004661     History of Changes
Other Study ID Numbers: 199/11909, UCLA-541
Study First Received: February 24, 2000
Last Updated: June 23, 2005
Health Authority: United States: Federal Government

Keywords provided by Office of Rare Diseases (ORD):
endocrine disorders
pseudohypoparathyroidism
rare disease

Additional relevant MeSH terms:
Pseudohypoparathyroidism
Pseudopseudohypoparathyroidism
Bone Diseases, Metabolic
Bone Diseases
Musculoskeletal Diseases
 Metal Metabolism, Inborn Errors
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Calcium Metabolism Disorders
Metabolic Diseases

ClinicalTrials.gov processed this record on May 22, 2013